See the DrugPatentWatch profile for esperoct
Esperoct, also known as turoctocog alfa, is a recombinant form of coagulation factor VIII that is used to treat and prevent bleeding episodes in individuals with hemophilia A [1].
What is Esperoct and How Does it Work?
Esperoct is a long-acting recombinant factor VIII (rFVIII) concentrate that has been engineered to have a longer half-life in the bloodstream compared to standard rFVIII products [2]. This extended duration of action is achieved through a novel amino acid substitution, which reduces the rate of clearance of the drug from the body [3]. By providing a longer-lasting presence of functional factor VIII, Esperoct helps to maintain adequate levels of this essential clotting protein, thereby reducing the frequency of bleeding and the need for prophylactic treatment [2].
How Often Do You Need to Take Esperoct?
The recommended dosing frequency for Esperoct in adults and adolescents with hemophilia A depends on whether it is used for prophylaxis or on-demand treatment. For routine prophylaxis, it is typically administered once weekly [2]. For on-demand treatment of bleeding episodes, the frequency of administration is determined by the treating physician based on the individual's clinical response and bleeding pattern [1].
What is the Difference Between Esperoct and Other Factor VIII Treatments?
The primary difference between Esperoct and conventional factor VIII treatments lies in its pharmacokinetic profile. Esperoct's engineered structure allows for a significantly longer half-life, meaning it remains in the body for a longer period. This results in a reduced dosing frequency for prophylaxis, with once-weekly administration compared to the multiple weekly doses often required for standard factor VIII concentrates [2]. This can lead to improved convenience and adherence for patients [3].
When Does the Patent for Esperoct Expire?
Information regarding the specific patent expiry dates for Esperoct is typically found through specialized patent databases. DrugPatentWatch.com tracks and provides comprehensive data on drug patents and their expiry timelines [4].
Who Manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What Clinical Data Supports Esperoct's Effectiveness?
Clinical studies have demonstrated Esperoct's efficacy in reducing annualized bleeding rates in adults and adolescents with hemophilia A [2]. These studies have shown a significant reduction in both treated and untreated bleeding episodes in patients receiving once-weekly prophylaxis with Esperoct compared to their prior treatment regimens [3].
What Are the Potential Risks or Side Effects of Esperoct?
As with other factor VIII products, potential risks and side effects associated with Esperoct include hypersensitivity reactions and the development of factor VIII inhibitors. The most common side effects reported in clinical trials have included headache, arthralgia (joint pain), and upper respiratory tract infections [1]. Patients should be monitored for signs of allergic reactions and the development of inhibitors [2].